COYA - MCAP CO - Coya Therapeutics, Inc.

The price chart for Coya Therapeutics, Inc. (COYA) clearly illustrates the approach to automating Treg cell analysis via IT platforms for drug discovery. The price action, where the market capitalization stands at 0.12, depends exclusively on the progress of clinical trials, ignoring macroeconomic factors. The business relies on innovative Treg therapy that restores immunity to combat amyotrophic lateral sclerosis, unlocking new opportunities in the treatment of neurodegeneration.

Market capitalization reflects the aggregate value of all shares, reacting instantaneously to market sentiment and liquidity. Analyzing volatility through the issuer's current capitalization allows for an assessment of the asset's resilience to panic selling. The trend of this metric determines the balance between growth potential and the risks of capital freeze. For Coya Therapeutics, Inc. (COYA), this metric visualizes the market valuation of breakthrough developments in neuroprotection. The company's value depends directly on the prospects of T-cell therapy for Alzheimer's and ALS.